Medical Cannabis Research Pioneer Cure Pharma Soldiers On, Hoping to Deliver Where Zynerba Failed

Trends in the medical marijuana industry continue to make headlines as the early polling favorite in New Jersey’s upcoming gubernatorial election has expressed clear support for full legalization of both recreational and medical cannabis sales.  This has prompted key players in the $6 billion US market to devote significant resources in aiding state efforts to approve new medical marijuana dispensaries.  It has been reported that the Democratic-controlled New Jersey legislature already has a pro-legalization bill ready to be signed if early polling numbers in the statewide election prove to be accurate.  

So, it is clear that this is an issue that is not going to fade away from the headlines anytime soon, and investors are looking for ways to ramp-up industry exposure through companies that are well-positioned to benefit from these continued legislative efforts.

A leading innovator in the space is Cure Pharmaceutical Corp. (OTCQB: CURR), which recently entered into strategic partnerships with the Technion-Israel Institute of Technology to develop innovative prostate cancer and leukemia treatments through the use of cannabinoid compounds (CBDs).  Technion will be responsible for conducting the studies (as human trials can be completed more quickly in Israel), and Cure will identify which cannabinoid molecules are most suitable for examination.  The results of the research will better enable doctors to match cancer subtypes with the most appropriate cannabis extracts in order to maximize treatment efficacy.

“This research partnership with Technion, which has one of the leading cannabis laboratories in the world, is a crucial step in our goal to bring new cancer-fighting cannabinoid molecules to market,” said Rob Davidson, CEO of Cure Pharmaceuticals. “In this work the Technion team aims to clarify the antitumor effects of phytocannabinoids and terpenes on various cancer-driving mutations and pathways, as well as further elucidating the mechanism of the cannabinoid-mediated antitumor effects. This will allow not only the identification of new drug candidates but also will create the ability to optimize cannabis treatment options for patients. Together these options further efforts toward the creation of personalized medicine.”

Cure hopes to succeed in areas where companies like Zynerba Pharmaceuticals (NASDAQ: ZYNE) have failed in the past.  Zynerba’s inability to meet primary and secondary endpoints in clinical trials for its adult epilepsy treatments has shown that the barriers to entry are high for CBD-related products.  Overcoming these barriers ultimately requires next-level innovation and disruptive technologies that are truly capable of modernizing the medical marijuana industry, meeting patient needs, and filling in the gaps that have been missed with the use of traditional medicine.

“Our goal is to bring new cannabinoid molecules to market through the FDA regulatory process, while utilizing our company’s proprietary delivery technologies to increase efficacy, as well as target unmet needs in traditional pharmaceutical markets that could be disrupted by cannabinoid-based options,” Davidson said.

Progress on these fronts has already been realized.  Technion’s lab group recently discovered two new pathways that have been activated by cannabis extracts in cancer cells, and Cure Pharma has introduced its CureFilm drug delivery system, which is an industry-disruptive technology that has already secured its position as the most advanced oral thin film available in the market today.

Oral thin films have been shown to improve bioavailability, increase patient compliance, and allow for drug administration that is more convenient for all patient types.  A sort of Listerine PocketPack for drug delivery, CureFilm is more stable and durable than other oral thin films competing in the market — and it enables the transmission of multiple active pharmaceutical ingredients — or APIs — through a single strip.

Recent market research reports have suggested the global thin film drug manufacturing market will be worth US $15.9 billion by the end of 2024, and Cure Pharma’s newest product offerings have paved the way for these types of drug delivery mechanisms to receive recognition in the biotechnology market.  

All combined, Cure Pharmaceutical’s strategic moves have opened doors to innovation in difficult regulatory environments in ways that will allow cannabinoid researchers to advance clinical programs, accelerate the time-to-market for needed treatments, and increase the safety and efficacy profile of the drugs that are available to patients.  These trends are attracting the attention of biotech investors and industry professionals looking to gain access to leading companies and disruptive technologies advancing the market today.

Leave a Reply

Your email address will not be published. Required fields are marked *